Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 13 recruiting now early-phase tilt

Bronchopulmonary Dysplasia: early-phase trial registry

13 of 30 indexed Bronchopulmonary Dysplasia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #519 of 28,707 conditions by registered trial count.

30 US clinical trials · 13 currently recruiting · #519 of 28,707 conditions by registered trial count

Bronchopulmonary Dysplasia: 30 US clinical trials tracked, 13 recruiting.

Bronchopulmonary Dysplasia is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is University of Alabama at Birmingham, running 3 of these trials.

Enrollment posture brief

Registry condition bronchopulmonary-dysplasia

OPEN 13 | RECR 43% | LATE 4 | EARLY 9 | RANK #519 | SPON 3

Nearest open-share peer: Chronic Lymphocytic Leukemia (CLL) (43% recruiting · 30 trials)

AML60%Bronchopulmonary Dysplas (th…43%Acute Myeloid Leukemia40%Anatomic Stage IA Breast Can26.7%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia lists 13 open slots (43% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bronchopulmonary Dysplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bronchopulmonary Dysplasia is recruiting above its size-band peers.

    13 of 30 indexed trials (43.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Bronchopulmonary Dysplasia trials is spread across many organizations.

    University of Alabama at Birmingham accounts for 3 of 30 trials (10%). 23 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bronchopulmonary Dysplasia enrolment sits around 130 participants.

    Median target enrolment is 130 among the 30 trials that report a genuine target (sentinel values excluded). 12 of those (40%) plan for fewer than 100 participants.

  4. Bronchopulmonary Dysplasia research is mostly interventional.

    23 interventional and 7 observational studies make up this index (76.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 26Phase 34

Open and recent trials

30 total, page 1 of 1

RECRUITING NA 700 participants

Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

University of Texas Southwestern Medical Center

NCT05849077

RECRUITING NA 478 participants

The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial

University of Pennsylvania

NCT05446272

RECRUITING Phase 2 338 participants

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

OHB Neonatology

NCT03253263

RECRUITING NA 222 participants

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Shirley Ryan AbilityLab

NCT05568264

RECRUITING NA 218 participants

Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

University of Florida

NCT06000761

RECRUITING 160 participants

MRI in BPD Subjects

Children's Hospital Medical Center, Cincinnati

NCT03657693

RECRUITING 130 participants

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

Children's Hospital of Philadelphia

NCT06475976

RECRUITING 90 participants

Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

University of Colorado, Denver

NCT03797183

RECRUITING 80 participants

Forced Oscillometry in Infants With Bronchopulmonary Dysplasia

Winston Manimtim

NCT04270045

RECRUITING NA 60 participants

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

Children's Hospital of Philadelphia

NCT06534359

RECRUITING Phase 1 30 participants

Inhaled Ciclesonide Study in Preterm Infants

Venkatesh Sampath

NCT06589245

RECRUITING NA 25 participants

Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study

Le Bonheur Children's Hospital

NCT06821776

RECRUITING NA 24 participants

Ventilator Pressure and Optimization of Compliance and Hemodynamics

University of Alabama at Birmingham

NCT06512935

ACTIVE NOT RECRUITING NA 600 participants

Pulmonary Function Using Non-invasive Forced Oscillometry

University of Alabama at Birmingham

NCT03346343

ACTIVE NOT RECRUITING 526 participants

Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

Nationwide Children's Hospital

NCT03782610

ACTIVE NOT RECRUITING 300 participants

A Cohort Study of the Intestinal Microbiota of Premature Infants

University of California, Davis

NCT03717584

COMPLETED Phase 3 800 participants

Hydrocortisone for BPD

NICHD Neonatal Research Network

NCT01353313

COMPLETED Phase 3 511 participants

Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Roberta Ballard

NCT01022580

COMPLETED Phase 3 451 participants

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

Mallinckrodt

NCT00931632

COMPLETED 277 participants

Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies

University of Rochester

NCT01607216

COMPLETED Phase 2 220 participants

Trial II of Lung Protection With Azithromycin in the Preterm Infant

Hubert Ballard

NCT00319956

COMPLETED Phase 2 109 participants

Safety of Sildenafil in Premature Infants

University of North Carolina, Chapel Hill

NCT03142568

COMPLETED Phase 1 104 participants

Delivery Room CPAP in Extremely Low Birth Weight Infants

NICHD Neonatal Research Network

NCT01223274

COMPLETED Phase 2 100 participants

Vitamin D Supplementation for Extremely Preterm Infants

University of Alabama at Birmingham

NCT01600430

COMPLETED Phase 2 88 participants

Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

Tufts Medical Center

NCT01941745

COMPLETED Phase 3 85 participants

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

Roberta Ballard

NCT00569530

COMPLETED Phase 2 82 participants

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

University of North Carolina, Chapel Hill

NCT02527798

COMPLETED NA 20 participants

Relationship Between EIT and Respiratory Status in Very Preterm Infants

Lawrence Rhein

NCT06609135

COMPLETED NA 15 participants

Work of Breathing During Non-invasive Ventilation in Premature Neonates

Arkansas Children's Hospital Research Institute

NCT02788110

COMPLETED Phase 1 9 participants

Montelukast in Very Low Birthweight Infants

Children's Hospital Medical Center, Cincinnati

NCT00492102

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 4

Named interventions

Most-linked intervention names on Bronchopulmonary Dysplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Non-invasive forced airway oscillometry Device
2 trials
Placebo Other
2 trials
Sham (No Treatment) Drug
1 trials
Infasurf surfactant (ONY, Inc.) Drug
1 trials
High dose rhCC10 Drug
1 trials
Low Dose rhCC10 Drug
1 trials
Half normal saline Drug
1 trials

US sites by state

Facility locations filed on Bronchopulmonary Dysplasia trials. A trial with sites in several states counts in each.

California 10 trials
Ohio 8 trials
Missouri 8 trials
Florida 8 trials
New York 7 trials
Illinois 7 trials
North Carolina 6 trials
Kentucky 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bronchopulmonary Dysplasia page

30 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bronchopulmonary Dysplasia condition card totals 30 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.